Visit | Budesonide–formoterol ‘as needed’, n (%) | Budesonide maintenance two times per day, n (%) | ||||||
N | ‘Well-controlled’ ≤ 0.75 | ‘Partly controlled’ 0.75 to <1.5 | ‘Inadequately controlled’ ≥1.5 | N | ‘Well-controlled’ ≤0.75 | ‘Partly controlled’ 0.75 to <1.5 | ‘Inadequately controlled’ ≥1.5 | |
Visit 1 (Baseline) | 437 | 146 (33.4) | 170 (38.9) | 121 (27.7) | 448 | 154 (34.4) | 161 (35.9) | 133 (29.7) |
Visit 2 (Week 4) | 423 | 169 (40.0) | 180 (42.6) | 74 (17.5) | 427 | 202 (47.3) | 155 (36.3) | 70 (16.4) |
Visit 3 (Week 16) | 409 | 177 (43.3) | 168 (41.1) | 64 (15.7) | 399 | 222 (55.6) | 113 (28.3) | 64 (16.0) |
Visit 4 (Week 28) | 389 | 211 (54.2) | 116 (29.8) | 62 (15.9) | 377 | 211 (56.0) | 98 (26.0) | 68 (18.0) |
Visit 5 (Week 40) | 377 | 198 (52.5) | 121 (32.1) | 58 (15.4) | 367 | 211 (57.5) | 96 (26.2) | 60 (16.4) |
Visit 6 (Week 52)* | 403 | 220 (54.6) | 111 (27.5) | 72 (17.9) | 406 | 237 (58.4) | 103 (25.4) | 66 (16.3) |
End of study (LOCF)† | 434 | 228 (52.5) | 126 (29.0) | 80 (18.4) | 431 | 242 (56.2) | 116 (26.9) | 73 (16.9) |
*Visit 6 represents ACQ-5 scores collected at withdrawal from the study or at completion of the study (week 52)
†LOCF except if only a baseline reading was available; the number missing any observations after baseline was 3 for budesonide–formoterol ‘as needed’ 17 for budesonide maintenance two times per day.
ACQ-5, Asthma Control Questionnaire Version 5; LOCF, last observation carried forward; n, number of patients in each ACQ-5 category; N, number of patients in each treatment group at each visit.